This study investigated whether a melanocyte-intrinsic transcriptional program drives immune tolerance to UV-induced mutations, focusing on the role of MITF in regulating PD-L1 expression in primary human melanocytes, iPSC-derived melanocytes, and a murine melanocyte-restricted Pd-l1 knockout model.
MITF directly activated PD-L1 transcription via a conserved upstream enhancer with functional E-box elements, independent of interferon signaling. Melanocyte-restricted Pd-l1 deletion in mice triggered CD8+ T cell infiltration and depigmentation after long-term UVB exposure (recapitulating vitiligo), and PD-L1-deficient iPSC-derived melanocytes showed increased apoptosis and greater susceptibility to gp100-specific CD8+ T cell killing.
Findings rely on in vitro (primary melanocytes, iPSC-derived cells) and murine models, which may not fully capture human in vivo immune dynamics; the study does not directly demonstrate the MITF-PD-L1 axis driving early melanoma immune evasion in human patients; iPSC-derived melanocytes may differ functionally from primary adult melanocytes.
The MITF-PD-L1 axis in melanocytes may explain both the autoimmune depigmentation seen with PD-1/PD-L1 blockade (vitiligo as an on-target effect) and the intrinsic responsiveness of melanoma to checkpoint inhibitors. Clinicians should recognize that melanocytic PD-L1 expression is a lineage-specific, UV-inducible program—not solely driven by inflammation—which has implications for interpreting PD-L1 tumor biomarker testing in melanoma.
Explore related topics
